Cadent Therapeutics Appoints John McBride CFO

Xconomy Boston — 

John McBride has been appointed chief financial officer of Cadent Therapeutics. He was most recently the CFO of Syntimmune, which was acquired by Alexion Pharmaceuticals (NASDAQ: ALXN) last year. Cambridge, MA-based Cadent raised $40 million in financing last November to advance its lead drug into Phase 2 testing for two movement disorders.